Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;1(1):3-7.
doi: 10.3892/etm_00000001. Epub 2010 Jan 1.

The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications

Foteini Economidou  1 , George Margaritopoulos, Katerina M Antoniou, Nikolaos M Siafakas
Affiliations

The angiogenetic pathway in malignant pleural effusions: Pathogenetic and therapeutic implications

Foteini Economidou et al. Exp Ther Med. 2010 Jan.

Abstract

Increased permeability of the pleural microvasculature is generally attributed to the substances that are released in inflammatory and malignant pleural effusions, although the exact pathogenetic mechanisms of malignant pleural effusions are unclear. Current therapies used to prevent the re-accumulation of pleural fluid and relieve symptoms are of variable efficacy and may cause serious adverse effects. Understanding the mechanisms of fluid accumulation would hopefully permit the development of more specific, effective and safer treatment modalities. Angiogenesis, pleural vascular increased permeability and inflammation are considered central to the pathogenesis of malignant pleural effusions. Vascular endothelial growth factor (VEGF) is a member of the VEGF/platelet-derived factor gene family and consists of at least six isoforms. Since it was shown that VEGF contributes to the formation of malignant pleural effusions, there have been some attempts to implicate, therapeutically, this finding using different molecules (ZD6474, PTK 787 and bevacizumab). However, the role of the biological axis of VEGF and angiopoietins needs further investigation in both the pathogenesis and the treatment of malignant pleural effusion. In both non-small-cell lung carcinoma and breast cancer, it has been shown that the ligand for CXCR4, CXCL12 or SDF-1α, exhibited peak levels of expression in organs that were the preferred destination for their respective metastases. Recent findings imply that new therapeutic strategies aimed at blocking the SDF-1-CXCR4 axis may have significant applications for patients by modulating the trafficking of hemato/lymphopoietic cells and inhibiting the metastatic behavior of tumor cells as well. The purpose of this report is to review novel pathogenetic and therapeutic implications regarding the angiogenetic pathways in malignant pleural effusions.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee YC, Light RW. Management of malignant pleural effusions. Respirology. 2004;9:148–156. - PubMed
    1. Antony VE, Loddenkepmper R, Astoul P, et al. Management of malignant pleural effusions. Am J Resp Crit Care Med. 2000;162:1987–2001. - PubMed
    1. West SD, Davies RJ, Lee YC. Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med. 2004;10:305–310. - PubMed
    1. Kinasewitz GT. Transudative effusions. Eur Respir J. 1997;10:714–718. - PubMed
    1. Light RW. Pleural diseases. Dis Mon. 1992;38:261–331. - PubMed

LinkOut - more resources